BiomeBank

BiomeBank is an Australian biotechnology company leading the development of co-cultured microbiome-based therapies. Their proprietary CONSORTIOMETM platform enables the targeted cultivation of stable, defined microbial consortia, overcoming the limitations of donor-derived approaches and unlocking new therapeutic potential.

With the world’s largest gut microbiome collection, BiomeBank is at the forefront of microbiome drug development. Their lead candidate, BB265, a live biotherapeutic product (LBP) for ulcerative colitis, has over 100 carefully selected strains that collectively deliver over 93 per cent of the therapeutic function of a healthy microbiome. Through advanced co-culturing techniques, BiomeBank engineers complex microbial communities under controlled conditions, ensuring consistency, scalability, and efficacy.

BiomeBank has transformed the regulatory landscape for microbiome-based medicines, securing the world’s first regulatory approval for a microbiome therapy and setting new standards for quality and safety in the field. Their research and production facility in South Australia integrates cutting-edge microbiology, bioinformatics, and bioprocessing to develop high-quality, clinically validated therapies.

With a strong pipeline and a clear commercial pathway, BiomeBank is shaping the future of microbiome therapeutics.

BiomeBank welcomes collaboration with biopharma companies and investors to harness the full potential of the microbiome in transforming human health.